115 related articles for article (PubMed ID: 19875509)
1. In vitro interactions between primycin and different statins in their effects against some clinically important fungi.
Nyilasi I; Kocsubé S; Pesti M; Lukács G; Papp T; Vágvölgyi C
J Med Microbiol; 2010 Feb; 59(Pt 2):200-205. PubMed ID: 19875509
[TBL] [Abstract][Full Text] [Related]
2. In vitro synergistic interactions of the effects of various statins and azoles against some clinically important fungi.
Nyilasi I; Kocsubé S; Krizsán K; Galgóczy L; Pesti M; Papp T; Vágvölgyi C
FEMS Microbiol Lett; 2010 Jun; 307(2):175-84. PubMed ID: 20636975
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility of clinically important dermatophytes against statins and different statin-antifungal combinations.
Nyilasi I; Kocsubé S; Krizsán K; Galgóczy L; Papp T; Pesti M; Nagy K; Vágvölgyi C
Med Mycol; 2014 Feb; 52(2):140-8. PubMed ID: 24004389
[TBL] [Abstract][Full Text] [Related]
4. Antifungal activity of statins against Aspergillus species.
Qiao J; Kontoyiannis DP; Wan Z; Li R; Liu W
Med Mycol; 2007 Nov; 45(7):589-93. PubMed ID: 18033614
[TBL] [Abstract][Full Text] [Related]
5. Interactions between statins and Penicillium chrysogenum antifungal protein (PAF) to inhibit the germination of sporangiospores of different sensitive Zygomycetes.
Galgóczy L; Papp T; Lukács G; Leiter E; Pócsi I; Vágvölgyi C
FEMS Microbiol Lett; 2007 May; 270(1):109-15. PubMed ID: 17302920
[TBL] [Abstract][Full Text] [Related]
6. Are the Statins promising antifungal agents against invasive candidiasis?
Lima WG; Alves-Nascimento LA; Andrade JT; Vieira L; de Azambuja Ribeiro RIM; Thomé RG; Dos Santos HB; Ferreira JMS; Soares AC
Biomed Pharmacother; 2019 Mar; 111():270-281. PubMed ID: 30590315
[TBL] [Abstract][Full Text] [Related]
7. Antifungal activities and cytotoxicity studies of six new azasordarins.
Herreros E; Almela MJ; Lozano S; Gomez de las Heras F; Gargallo-Viola D
Antimicrob Agents Chemother; 2001 Nov; 45(11):3132-9. PubMed ID: 11600368
[TBL] [Abstract][Full Text] [Related]
8. In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens.
Uchida K; Nishiyama Y; Yokota N; Yamaguchi H
J Antibiot (Tokyo); 2000 Oct; 53(10):1175-81. PubMed ID: 11132964
[TBL] [Abstract][Full Text] [Related]
9. Synergistic antifungal activity of statin-azole associations as witnessed by Saccharomyces cerevisiae- and Candida utilis-bioassays and ergosterol quantification.
Cabral ME; Figueroa LI; Fariña JI
Rev Iberoam Micol; 2013 Jan; 30(1):31-8. PubMed ID: 23069981
[TBL] [Abstract][Full Text] [Related]
10. Antifungal activity of statins and their interaction with amphotericin B against clinically important Zygomycetes.
Galgóczy L; Lukács G; Nyilasi I; Papp T; Vágvölgyi C
Acta Biol Hung; 2010 Sep; 61(3):356-65. PubMed ID: 20724281
[TBL] [Abstract][Full Text] [Related]
11. Effect of fluvastatin and pravastatin, HMG-CoA reductase inhibitors, on fluconazole activity against Candida albicans.
Nash JD; Burgess DS; Talbert RL
J Med Microbiol; 2002 Feb; 51(2):105-109. PubMed ID: 11863260
[TBL] [Abstract][Full Text] [Related]
12. Growth inhibition of Candida species and Aspergillus fumigatus by statins.
Macreadie IG; Johnson G; Schlosser T; Macreadie PI
FEMS Microbiol Lett; 2006 Sep; 262(1):9-13. PubMed ID: 16907733
[TBL] [Abstract][Full Text] [Related]
13. [The effect of propyl gallate on the activity of various antifungal drugs against filamentous fungi in vitro].
Xu Y; Pang GR; Lü XF; Chen ZJ; Sun ST; Song JZ
Zhonghua Yan Ke Za Zhi; 2006 Apr; 42(4):309-12. PubMed ID: 16762206
[TBL] [Abstract][Full Text] [Related]
14. Antifungal effects of statins.
Tavakkoli A; Johnston TP; Sahebkar A
Pharmacol Ther; 2020 Apr; 208():107483. PubMed ID: 31953128
[TBL] [Abstract][Full Text] [Related]
15. Statin Concentrations Below the Minimum Inhibitory Concentration Attenuate the Virulence of Rhizopus oryzae.
Bellanger AP; Tatara AM; Shirazi F; Gebremariam T; Albert ND; Lewis RE; Ibrahim AS; Kontoyiannis DP
J Infect Dis; 2016 Jul; 214(1):114-21. PubMed ID: 26984141
[TBL] [Abstract][Full Text] [Related]
16. Determination of MICs of aminocandin for Candida spp. and filamentous fungi.
Isham N; Ghannoum MA
J Clin Microbiol; 2006 Dec; 44(12):4342-4. PubMed ID: 17021057
[TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibility testing of amorolfine in pathogenic fungi isolated from dermatomycosis patients in China.
Li RY; Wan Z; Wang AP; Shen YN; Lu CM; Li M; Xi LY; Liu WD; Zeng FQ
Mycoses; 2004 Oct; 47(9-10):402-6. PubMed ID: 15504124
[TBL] [Abstract][Full Text] [Related]
18. Comparison of in vitro antifungal activities of amphotericin B lipid complex with itraconazole against 708 clinical yeast isolates and opportunistic moulds determined by National Committee for Clinical Laboratory Standards methods M27-A and M38-P.
Carrillo-Muñoz AJ; Ruesga M; Brio S; del Valle O; Rodriguez V; Santos P; Hernández-Molina JM; Cantón E; Pemán J; Guarro J; Quindós G
Chemotherapy; 2002 Dec; 48(5):224-31. PubMed ID: 12476038
[TBL] [Abstract][Full Text] [Related]
19. A head-on comparison of the in vitro antifungal activity of conventional and lipid-based amphotericin B: a multicenter study.
Jessup C; Reyes G; Fothergill A; McCarthy D; Rinaldi M; Messer S; Pfaller M; Ghannoum M
J Chemother; 2000 Feb; 12(1):22-9. PubMed ID: 10768512
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility of clinical isolates of fungi to saperconazole.
Otcenásek M
Mycopathologia; 1992 Jun; 118(3):179-83. PubMed ID: 1528231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
